NEWS: MAY 2006

-05/19/2006-

Press Release: Velocity11, a supplier of pioneering automation technology solutions for life science laboratories, has recently expanded the range of service and support accessible to customers via its website - www.velocity11.com. To read press release click here.

Targacept Inc. releases positive results from its Phase II clinical trial of TC-1734 (AZD3480) in age associated memory impairment. To read article click here.

-05/18/2006-

Press Release: INTEGRA Biosciences AG (Chur,Switzerland) a leading international manufacturer of innovative labtools for microbiology for over 20 years, has recently announced a new distribution agreement with Microbiology International (Frederick, MD) to further enhance its North American sales and support. To read press release click here.

FDA panel gives thumbs up to Merck's cervical cancer vaccine Gardasil. To read article click here.

Bristol-Myers Squibb stops the development of its oral diabetes type II drug Muraglitazar. To read article click here.

Albany Molecular Research Inc. begins the construction of a new 50,000 sq. ft. center in India. To read article click here.

Dr. Christopher Lipinski joins Medisyn Technologies Inc.'s Blue-Chip Scientific Advisory Board. To read article click here.

Merck launches new edition of The Merck Manual. To read article click here.

-05/17/2006-

Press Release: Aureus Pharma, ChemAxon, Budapest University of Technology and sanofi-aventis Collaborate on European Project related to Toxicity. To read press release click here.

Press Release: Activotec has recently completed a significant funding round to enable it to accelerate the growth of the company. To read press release click here.

deCODE genetics begins Phase III clinical trials of DG031 for heart attack prevention. To read article click here.

FDA approves Teva Pharmaceutical Industries Ltd.'s drug Azilect for Parkinson's disease. To read article click here.

Amicus Therapeutics Inc. goes IPO. To read article click here.

Vertex Pharmaceuticals Inc. beginst Phase I clinical trials of VX-770 for cystic fibrosis (CF). To read article click here.

Pfizer selects Rigel Pharmaceuticals, Inc.'s anti-allergic asthma candidate R343 for preclinical development. To read article click here.

MorphoSys and Schering-Plough form R&D collaboration. To read article click here.

-05/16/2006-

Press Release: Guava Technologies Inc. today announced that Guava has received 510(k) clearance from the U.S. Food and Drug Administration for the Guava® EZCD4 System. To read press release click here.

FDA rejects Neurocrine Biosciences Inc. and Pfizer Inc.'s drug Indiplon for sleep disorder. To read article click here.

Elsevier MDL launches PharmaPendium™. To read article click here.

-05/15/2006-

AstraZeneca to acquire Cambridge Antibody Technology (CAT) for $1.3 billion dollars. To read article click here.